Merck has received antitrust clearance from the competition authorities in Germany and Austria to tender an offer for the acquisition of clinical-stage biopharmaceutical firm Acceleron Pharma.
The latest move follows a definitive agreement signed by the company for the acquisition last month.
Related: Merck To Buy Acceleron For US$11.5B
Merck, through its subsidiary, commenced a cash tender offer to acquire Acceleron’s all outstanding shares, for US$180 per share, as announced on October 12 of this year.
Merck stated, “As previously announced on 29 October 2021, the tender offer will expire at 5:00 p.m., Eastern Time, on 18 November 2021, unless further extended in accordance with the merger agreement and the applicable rules and regulations of the SEC.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
